KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) Starts Presentation at 30th Annual ROTH Conference
KalVista Pharmaceuticals (NASDAQ: KALV) is a clinical-stage pharmaceutical company that discovers, develops, and commercializes small molecule protease inhibitors to treat diseases with significant unmet need. The company’s proprietary portfolio comprises of novel, small molecule plasma kallikrein inhibitors primarily targeting hereditary angioedema (“HAE”) and diabetic macular edema (“DME”). KalVista’s most advanced program, KVD001, has successfully completed its first-in-human study in patients with DME and commenced a phase 2 clinical trial in 2017. For more information, visit the company’s website at www.kalvista.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of…







